Gaoma Therapeutics develops bioactive lipid derivatives to create therapeutic molecules targeting neurological and inflammatory diseases. Their approach focuses on unique mechanisms of action to provide new treatment options for patients with unmet medical needs.
Funding
$1.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many neurological and inflammatory diseases lack effective treatments, leaving patients with unmet medical needs. Current therapies often have limited efficacy or significant side effects, highlighting the need for novel therapeutic approaches.
Solution
Gaoma Therapeutics develops innovative drug candidates based on bioactive lipid derivatives, targeting neurological and inflammatory diseases. Their approach focuses on identifying and developing molecules with unique mechanisms of action, differentiating them from existing treatments. By tapping into the pharmacological potential of complex lipids, Gaoma aims to create adapted therapeutic solutions for patients with limited options.
Target Audience
The primary target audience includes patients suffering from neurological and inflammatory diseases, as well as healthcare providers seeking new therapeutic options for these conditions.
Features
- Focus on lipid derivatives with innovative mechanisms of action.
- Pipeline includes GAO-3-02 and GAO-11-02.
- Research and development of drug candidates for neurological and inflammatory diseases.